risedronate

Ligand id: 3176

Name: risedronate

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: risedronate

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 5
Rotatable bonds 4
Topological polar surface area 167.8
Molecular weight 283
XLogP -3
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Bisphosphonate drug used to strenghten bone in the treatment of Pagets's disease and the prevention or treatment of osteoporosis.
Mechanism Of Action and Pharmacodynamic Effects
Risedronate acts by inhibiting osteoclast activity and reduces boen reabsorption and turnover. This is due to its affinity for bone mineral matrix component hydroxyapatite, and its inhibition of enzyme farnesyl diphosphate synthase (FPP synthase). FPP synthase inhibition prevents with synthesis of the isoprenoid lipids farnesyl diphosphate and geranylgeranyl diphosphate which are involved in post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins.
External links